Ignite Creation Date:
2025-12-25 @ 1:26 AM
Ignite Modification Date:
2026-02-28 @ 6:34 PM
Study NCT ID:
NCT02856893
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-10-31
First Post:
2016-07-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)
Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-10-10
Start Date Type:
ACTUAL
Primary Completion Date:
2022-09-20
Primary Completion Date Type:
ACTUAL
Completion Date:
2027-12
Completion Date Type:
ESTIMATED
First Submit Date:
2016-07-11
First Submit QC Date:
None
Study First Post Date:
2016-08-05
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2024-03-07
Results First Submit QC Date:
None
Results First Post Date:
2025-10-31
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-21
Last Update Post Date:
2025-10-31
Last Update Post Date Type:
ESTIMATED